The Epidermal Growth Factor Domain of the Mutation Does Not Appear to Influence Disease Progression in CADASIL When Brain Volume and Sex Are Taken into Account.


Journal

AJNR. American journal of neuroradiology
ISSN: 1936-959X
Titre abrégé: AJNR Am J Neuroradiol
Pays: United States
ID NLM: 8003708

Informations de publication

Date de publication:
05 2022
Historique:
received: 01 10 2021
accepted: 13 03 2022
pubmed: 30 4 2022
medline: 14 5 2022
entrez: 29 4 2022
Statut: ppublish

Résumé

By studying the evolution of brain volume across the life span in male and female patients, we aimed to understand how sex, brain volume, and the epidermal growth factor repeat domain of the mutation, the 3 major determinants of disability in CADASIL, interact in driving disease evolution. We used validated methods to model the evolution of normalized brain volume with age in male and female patients using nonparametric regression in a large, monocentric cohort with prospectively collected clinical and high-resolution MR imaging data. We used k-means clustering to test for the presence of different clinical course profiles. We included 229 patients (mean age, 53 [SD, 12] years; 130 women). Brain volume was larger in women (mean size, 1024 [SD, 62] cm Our results demonstrate a detrimental effect of male sex on brain volume throughout life in CADASIL. We identified a subgroup of male patients whose brain volume and clinical outcomes were similar to those of age-matched women. They did not have a specific distribution of the epidermal growth factor repeat domain, suggesting that yet-unidentified predictors may interact with sex and brain volume in driving disease evolution.

Sections du résumé

BACKGROUND AND PURPOSE
By studying the evolution of brain volume across the life span in male and female patients, we aimed to understand how sex, brain volume, and the epidermal growth factor repeat domain of the mutation, the 3 major determinants of disability in CADASIL, interact in driving disease evolution.
MATERIALS AND METHODS
We used validated methods to model the evolution of normalized brain volume with age in male and female patients using nonparametric regression in a large, monocentric cohort with prospectively collected clinical and high-resolution MR imaging data. We used k-means clustering to test for the presence of different clinical course profiles.
RESULTS
We included 229 patients (mean age, 53 [SD, 12] years; 130 women). Brain volume was larger in women (mean size, 1024 [SD, 62] cm
CONCLUSIONS
Our results demonstrate a detrimental effect of male sex on brain volume throughout life in CADASIL. We identified a subgroup of male patients whose brain volume and clinical outcomes were similar to those of age-matched women. They did not have a specific distribution of the epidermal growth factor repeat domain, suggesting that yet-unidentified predictors may interact with sex and brain volume in driving disease evolution.

Identifiants

pubmed: 35487587
pii: ajnr.A7499
doi: 10.3174/ajnr.A7499
pmc: PMC9089269
doi:

Substances chimiques

Epidermal Growth Factor 62229-50-9

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

715-720

Informations de copyright

© 2022 by American Journal of Neuroradiology.

Références

J Cereb Blood Flow Metab. 2016 Aug;36(8):1319-37
pubmed: 27170700
Lancet Neurol. 2013 Aug;12(8):822-38
pubmed: 23867200
Brain. 2006 Sep;129(Pt 9):2375-83
pubmed: 16844717
Stroke. 2016 Jan;47(1):4-11
pubmed: 26578659
Neuroinformatics. 2018 Apr;16(2):269-281
pubmed: 29594711
Neuroimage. 2002 Sep;17(1):479-89
pubmed: 12482100
Neuroimage. 2004;23 Suppl 1:S208-19
pubmed: 15501092
Neurology. 2016 Oct 25;87(17):1787-1795
pubmed: 27694265
Stroke. 2012 Jan;43(1):137-41
pubmed: 22033996
Genet Med. 2019 Mar;21(3):676-682
pubmed: 30032161
Neuroimage. 2016 Nov 1;141:191-205
pubmed: 27402600
J Cereb Blood Flow Metab. 2020 Feb;40(2):231-245
pubmed: 31744377
Neurosci Biobehav Rev. 2014 Feb;39:34-50
pubmed: 24374381
Front Neurol. 2018 Jul 10;9:526
pubmed: 30042721
J Alzheimers Dis. 2020;78(3):907-910
pubmed: 33074242
J Neurol. 2018 May;265(5):1158-1165
pubmed: 29549466

Auteurs

J Lebenberg (J)

the Centre de Neurologie Vasculaire Translationel (J.L., D.H., N.A., A.T., N.D.-G., H.C.), Assistance Publique-Hôpitaux de Paris, Hôpital Lariboisiere, Paris, France; L'Institut National de la Santé et de la RechercheMédicale INSERM U1141, Université Paris Cité, Paris, France.
Federation Hospitalo-Universitaire NeuroVasc (J.L., N.D.-G., D.H., H.C., E.J.), Paris, France.

J-P Guichard (JP)

Neuroradiology (J.P.G., A.G.).

A Guillonnet (A)

Neuroradiology (J.P.G., A.G.).

D Hervé (D)

the Centre de Neurologie Vasculaire Translationel (J.L., D.H., N.A., A.T., N.D.-G., H.C.), Assistance Publique-Hôpitaux de Paris, Hôpital Lariboisiere, Paris, France; L'Institut National de la Santé et de la RechercheMédicale INSERM U1141, Université Paris Cité, Paris, France.
Federation Hospitalo-Universitaire NeuroVasc (J.L., N.D.-G., D.H., H.C., E.J.), Paris, France.

N Alili (N)

the Centre de Neurologie Vasculaire Translationel (J.L., D.H., N.A., A.T., N.D.-G., H.C.), Assistance Publique-Hôpitaux de Paris, Hôpital Lariboisiere, Paris, France; L'Institut National de la Santé et de la RechercheMédicale INSERM U1141, Université Paris Cité, Paris, France.

A Taleb (A)

the Centre de Neurologie Vasculaire Translationel (J.L., D.H., N.A., A.T., N.D.-G., H.C.), Assistance Publique-Hôpitaux de Paris, Hôpital Lariboisiere, Paris, France; L'Institut National de la Santé et de la RechercheMédicale INSERM U1141, Université Paris Cité, Paris, France.

N Dias-Gastellier (N)

the Centre de Neurologie Vasculaire Translationel (J.L., D.H., N.A., A.T., N.D.-G., H.C.), Assistance Publique-Hôpitaux de Paris, Hôpital Lariboisiere, Paris, France; L'Institut National de la Santé et de la RechercheMédicale INSERM U1141, Université Paris Cité, Paris, France.
Federation Hospitalo-Universitaire NeuroVasc (J.L., N.D.-G., D.H., H.C., E.J.), Paris, France.

H Chabriat (H)

the Centre de Neurologie Vasculaire Translationel (J.L., D.H., N.A., A.T., N.D.-G., H.C.), Assistance Publique-Hôpitaux de Paris, Hôpital Lariboisiere, Paris, France; L'Institut National de la Santé et de la RechercheMédicale INSERM U1141, Université Paris Cité, Paris, France.
Federation Hospitalo-Universitaire NeuroVasc (J.L., N.D.-G., D.H., H.C., E.J.), Paris, France.

E Jouvent (E)

From the Department of Neurology (E.J.) eric.jouvent@aphp.fr.
Federation Hospitalo-Universitaire NeuroVasc (J.L., N.D.-G., D.H., H.C., E.J.), Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH